Dicerna Pharmaceuticals Inc (DRNA) 21.30 $DRNA
Dicerna to Present at the 2015 Leerink Global Healthcare Conference
Business Wire - Wed Feb 04, 3:15PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the 2015 Leerink Global Healthcare Conference. The presentation will take place at the Waldorf Astoria on Wednesday, February 11, 2015 at 1:00 p.m. ET in New York City.
DRNA: 21.30 (-0.06)
Dicerna Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Clinical Trial of DCR-MYC, an Investigational RNAi Therapeutic Targeting the MYC Oncogene, in Patients with Advanced Hepatocellular Carcinoma
Business Wire - Mon Feb 02, 6:30AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ
RNA), a leader in the development of RNAi therapeutics, today announced that the first patient has been dosed in a global Phase 1b/2 clinical trial of DCR-MYC, an investigational Dicer substrate short interfering RNA (DsiRNA) therapeutic, in patients with advanced hepatocellular carcinoma (HCC). This new trial expands the development program for DCR-MYC, which is also being studied in a Phase 1 clinical trial in patients with solid tumors and hematological malignancies.
DRNA: 21.30 (-0.06)
Dicerna Announces Issuance of US Patent Providing Broad Coverage of DsiRNA-EX RNAi Payloads
Business Wire - Mon Jan 12, 6:46AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ RNA), a leader in the development of RNAi therapeutics, today announced that the United States Patent and Trademark Office (USPTO) issued to Dicerna Patent No. 8,927,705, "Single Stranded Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression," on January 6, 2015.
DRNA: 21.30 (-0.06)
Dicerna Pharmaceuticals Presents Positive Preclinical Data on its DsiRNA Therapeutics Targeting MYC and B-Catenin at AACR MYC: From Biology to Therapy Meeting
Business Wire - Mon Jan 12, 6:45AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ RNA), a leader in the development of RNAi therapeutics, today announced the presentation of new preclinical data on its Dicer substrate short interfering RNA (DsiRNA) therapeutics targeting MYC and B-catenin (CTNNB1) oncogenes in models of hepatocellular carcinoma (HCC) and colorectal cancer (CRC). The positive data, presented during a poster session on January 9 at MYC: From Biology to Therapy, a meeting of the American Association of Cancer Research (AACR) in La Jolla, Calif., provide additional insights into the parameters that impact the delivery and activity of DsiRNA therapeutics utilizing Dicerna's proprietary EnCore(TM) lipid nanoparticle (LNP) technology in HCC and CRC tumor models.
DRNA: 21.30 (-0.06)
Can the Rally in Dicerna Pharmaceuticals (DRNA) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 6:27AM CST
Can the Rally in Dicerna Pharmaceuticals (DRNA) Shares Continue?
DRNA: 21.30 (-0.06)
Dicerna Announces the Appointment of Theodore T. Ashburn, M.D., Ph.D. to Senior Vice President, Product Strategy and Operations, and Inducement Grant of Stock Options under NASDAQ Listing Rule 5635 (c)(4)
Business Wire - Wed Dec 17, 5:36PM CST
Dicerna Pharmaceuticals, Inc. ("Dicerna" or the "Company"
(NASDAQ RNA), a leader in the development of RNAi-based therapeutics, today announced the appointment of Theodore (Ted) T. Ashburn, M.D., Ph.D. to Senior Vice President, Product Strategy and Operations. Dr. Ashburn brings 15 years of product and corporate development experience to Dicerna. In this newly-created position, Dr. Ashburn will lead product strategy and operational efforts for the Company's Dicer substrate short interfering RNAi (DsiRNA) therapeutics.
DRNA: 21.30 (-0.06)
Dicerna R&D Update Webcast Reminder
Business Wire - Mon Dec 15, 6:00AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ RNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, announces webcast and conference call information for its previously announced R&D Update webcast later today, December 15, 2014, at 4:30 p.m. Eastern Time.
DRNA: 21.30 (-0.06)
Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2014
M2 - Wed Dec 10, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/vv3g4v/alpha) has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alpha- Antitrypsin Deficiency - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alpha- Antitrypsin Deficiency pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Applied Genetic Technologies Corporation - Arrowhead Research Corporation - Carolus Therapeutics - Cevec Pharmaceuticals - Dicerna Pharmaceuticals - Grifols - iBio - International Stem Cell Corporation - Intrexon Corporation - Kamada - OrphageniX - Polyphor - rEVO Biologics - Sangamo BioSciences For more information visit http://www.researchandmarkets.com/research/vv3g4v/alpha
DRNA: 21.30 (-0.06), ARWR: 6.77 (+0.21), SGMO: 15.40 (+0.14), XON: 39.30 (+1.05), RBIO: ()
Marina Biotech: A Forgotten And Grossly Undervalued Game Changer
The GeoTeam - Seeking Alpha - Tue Nov 25, 9:30AM CST
Earlier this month, investors witnessed another RNAi stock achieve incredible gains based on very early clinical trial data. The company, Regulus Therapeutics (NASDAQ: RGLS ), published its Hepatitis-C Phase I data from a pool of only 16 patients....
ROSG: 3.65 (+0.32), ISIS: 63.86 (-0.43), DRNA: 21.30 (-0.06), ALNY: 95.54 (+1.67), ARWR: 6.77 (+0.21), SRPT: 12.76 (+0.11), ALXN: 182.29 (+6.02), TKMR: 21.45 (-0.22), RGLS: 16.85 (-0.13)
Dicerna to Present at the 2014 Deutsche Bank BioFEST
Business Wire - Tue Nov 25, 8:01AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ RNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, today announced that Douglas M. Fambrough, Ph.D., President and CEO, will present at the 2014 Deutsche Bank BioFEST. The presentation will take place at the Four Seasons Hotel Boston on December 1, 2014, at 4:00 p.m. ET in Boston, Mass.
DRNA: 21.30 (-0.06), DB: 32.29 (+0.70)
Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena Biopharma, and XOMA
PR Newswire - Tue Nov 18, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Geron Corporation (NASDAQ: GERN), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Galena Biopharma Inc. (NASDAQ: GALE), and XOMA Corporation (NASDAQ: XOMA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 17, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,647.75, up 0.07% and the NASDAQ Composite closed at 4,671.00, down 0.37%. The S&P 500 finished the session 0.07% higher at 2,041.32. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 781.08, up 0.49%, with the index advancing 9.06% in the previous three months. Register for your complimentary reports on these five stocks at:
DRNA: 21.30 (-0.06), GERN: 3.03 (unch), TKMR: 21.45 (-0.22), GALE: 1.68 (+0.06), XOMA: 3.41 (-0.01), EXEL: 2.48 (+0.20)
Tekmira inks deal with Dicerna
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 2:36PM CST
DRNA: 21.30 (-0.06), TKMR: 21.45 (-0.22)
Dicerna Reports on Progress of Development Programs
Business Wire - Mon Nov 17, 7:02AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ RNA), a leader in the development of RNA interference (RNAi) based therapeutics, today announced that it will host its first R&D webcast to review the company's strategy, technology, and expanding pipeline of innovative RNAi therapies. The R&D webcast will take place on Monday, December 15 at 4:30 p.m. To register, please visit www.dicerna.com.
DRNA: 21.30 (-0.06)
Dicerna Announces License Agreement with Tekmira to Advance Dicerna's PH1 Development Program
Business Wire - Mon Nov 17, 7:02AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ RNA), a leading developer of RNA interference (RNAi) therapeutics, today announced a licensing agreement for Dicerna to use Tekmira's proprietary lipid nanoparticle (LNP) technology for delivery of DCR-PH1, Dicerna's investigational product candidate for primary hyperoxaluria type 1 (PH1), a rare, inherited liver disorder that often results in kidney failure, and for which there are no approved therapies.
DRNA: 21.30 (-0.06)
Tekmira Announces Licensing and Collaboration Agreement With Dicerna
GlobeNewswire - Mon Nov 17, 7:00AM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM) a leading developer of RNA interference (RNAi) therapeutics, today announces a licensing and collaboration agreement with Dicerna Pharmaceuticals, Inc. Tekmira has licensed its proprietary lipid nanoparticle (LNP) delivery technology for exclusive use in Dicerna's primary hyperoxaluria type 1 (PH1) development program.
DRNA: 21.30 (-0.06), TKMR: 21.45 (-0.22), TKM.TO: 26.51 (-0.73)
Dicerna to Present at Two Upcoming Investor Conferences
Business Wire - Fri Nov 14, 3:40PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, today announced that Douglas M. Fambrough, Ph.D., President and CEO, will present at two upcoming conferences, including the Stifel 2014 Healthcare Conference and the Jefferies 2014 Global London Healthcare Conference.
DRNA: 21.30 (-0.06)
InsiderInsights.com Daily Round Up 11/10/14: CHK, TWX, SGEN, PBFX
InsiderInsights - at Seeking Alpha - Tue Nov 11, 2:29AM CST
HAS: 62.74 (+0.58), VR: 42.10 (+0.07), SEIC: 43.20 (+0.07), DRNA: 21.30 (-0.06), HA: 18.72 (-0.31), SAM: 303.26 (-0.97), PBFX: 23.40 (+0.95), AMRI: 16.94 (-0.28), GSAT: 2.40 (+0.08), TNET: 36.49 (+0.76), TWX: 83.87 (+0.56), HLT: 28.57 (+0.13), Q: 63.31 (+0.06), SGEN: 31.57 (+0.36), CF: 301.40 (-1.20), OPK: 13.80 (-0.28), CHK: 21.08 (+0.58), CNDO: 2.28 (+0.03), CO: 4.75 (-0.06), CPLA: 65.23 (-1.37)
Dicerna Pharmaceuticals' (DRNA) CEO Doug Fambrough on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 11:36AM CST
DRNA: 21.30 (-0.06)
Dicerna Pharmaceuticals beats by $0.09
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:24AM CST
DRNA: 21.30 (-0.06)
Dicerna Announces Third Quarter 2014 Financial and Operational Results
Business Wire - Thu Nov 06, 6:02AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, today announced financial and operational results for the quarter ended September 30, 2014.
DRNA: 21.30 (-0.06)
Dicerna to Present at the 2015 Leerink Global Healthcare Conference
Business Wire - Wed Feb 04, 3:15PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the 2015 Leerink Global Healthcare Conference. The presentation will take place at the Waldorf Astoria on Wednesday, February 11, 2015 at 1:00 p.m. ET in New York City.
DRNA: 21.30 (-0.06)
Dicerna Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Clinical Trial of DCR-MYC, an Investigational RNAi Therapeutic Targeting the MYC Oncogene, in Patients with Advanced Hepatocellular Carcinoma
Business Wire - Mon Feb 02, 6:30AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ
RNA), a leader in the development of RNAi therapeutics, today announced that the first patient has been dosed in a global Phase 1b/2 clinical trial of DCR-MYC, an investigational Dicer substrate short interfering RNA (DsiRNA) therapeutic, in patients with advanced hepatocellular carcinoma (HCC). This new trial expands the development program for DCR-MYC, which is also being studied in a Phase 1 clinical trial in patients with solid tumors and hematological malignancies. DRNA: 21.30 (-0.06)
Dicerna Announces Issuance of US Patent Providing Broad Coverage of DsiRNA-EX RNAi Payloads
Business Wire - Mon Jan 12, 6:46AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ
RNA), a leader in the development of RNAi therapeutics, today announced that the United States Patent and Trademark Office (USPTO) issued to Dicerna Patent No. 8,927,705, "Single Stranded Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression," on January 6, 2015. DRNA: 21.30 (-0.06)
Dicerna Pharmaceuticals Presents Positive Preclinical Data on its DsiRNA Therapeutics Targeting MYC and B-Catenin at AACR MYC: From Biology to Therapy Meeting
Business Wire - Mon Jan 12, 6:45AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ
RNA), a leader in the development of RNAi therapeutics, today announced the presentation of new preclinical data on its Dicer substrate short interfering RNA (DsiRNA) therapeutics targeting MYC and B-catenin (CTNNB1) oncogenes in models of hepatocellular carcinoma (HCC) and colorectal cancer (CRC). The positive data, presented during a poster session on January 9 at MYC: From Biology to Therapy, a meeting of the American Association of Cancer Research (AACR) in La Jolla, Calif., provide additional insights into the parameters that impact the delivery and activity of DsiRNA therapeutics utilizing Dicerna's proprietary EnCore(TM) lipid nanoparticle (LNP) technology in HCC and CRC tumor models. DRNA: 21.30 (-0.06)
Can the Rally in Dicerna Pharmaceuticals (DRNA) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 6:27AM CST
Can the Rally in Dicerna Pharmaceuticals (DRNA) Shares Continue?
DRNA: 21.30 (-0.06)
Dicerna Announces the Appointment of Theodore T. Ashburn, M.D., Ph.D. to Senior Vice President, Product Strategy and Operations, and Inducement Grant of Stock Options under NASDAQ Listing Rule 5635 (c)(4)
Business Wire - Wed Dec 17, 5:36PM CST
Dicerna Pharmaceuticals, Inc. ("Dicerna" or the "Company"
(NASDAQ RNA), a leader in the development of RNAi-based therapeutics, today announced the appointment of Theodore (Ted) T. Ashburn, M.D., Ph.D. to Senior Vice President, Product Strategy and Operations. Dr. Ashburn brings 15 years of product and corporate development experience to Dicerna. In this newly-created position, Dr. Ashburn will lead product strategy and operational efforts for the Company's Dicer substrate short interfering RNAi (DsiRNA) therapeutics. DRNA: 21.30 (-0.06)
Dicerna R&D Update Webcast Reminder
Business Wire - Mon Dec 15, 6:00AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ
RNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, announces webcast and conference call information for its previously announced R&D Update webcast later today, December 15, 2014, at 4:30 p.m. Eastern Time. DRNA: 21.30 (-0.06)
Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2014
M2 - Wed Dec 10, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/vv3g4v/alpha) has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alpha- Antitrypsin Deficiency - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alpha- Antitrypsin Deficiency pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Applied Genetic Technologies Corporation - Arrowhead Research Corporation - Carolus Therapeutics - Cevec Pharmaceuticals - Dicerna Pharmaceuticals - Grifols - iBio - International Stem Cell Corporation - Intrexon Corporation - Kamada - OrphageniX - Polyphor - rEVO Biologics - Sangamo BioSciences For more information visit http://www.researchandmarkets.com/research/vv3g4v/alpha
DRNA: 21.30 (-0.06), ARWR: 6.77 (+0.21), SGMO: 15.40 (+0.14), XON: 39.30 (+1.05), RBIO: ()
Marina Biotech: A Forgotten And Grossly Undervalued Game Changer
The GeoTeam - Seeking Alpha - Tue Nov 25, 9:30AM CST
Earlier this month, investors witnessed another RNAi stock achieve incredible gains based on very early clinical trial data. The company, Regulus Therapeutics (NASDAQ: RGLS ), published its Hepatitis-C Phase I data from a pool of only 16 patients....
ROSG: 3.65 (+0.32), ISIS: 63.86 (-0.43), DRNA: 21.30 (-0.06), ALNY: 95.54 (+1.67), ARWR: 6.77 (+0.21), SRPT: 12.76 (+0.11), ALXN: 182.29 (+6.02), TKMR: 21.45 (-0.22), RGLS: 16.85 (-0.13)
Dicerna to Present at the 2014 Deutsche Bank BioFEST
Business Wire - Tue Nov 25, 8:01AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ
RNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, today announced that Douglas M. Fambrough, Ph.D., President and CEO, will present at the 2014 Deutsche Bank BioFEST. The presentation will take place at the Four Seasons Hotel Boston on December 1, 2014, at 4:00 p.m. ET in Boston, Mass. DRNA: 21.30 (-0.06), DB: 32.29 (+0.70)
Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena Biopharma, and XOMA
PR Newswire - Tue Nov 18, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Geron Corporation (NASDAQ: GERN), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Galena Biopharma Inc. (NASDAQ: GALE), and XOMA Corporation (NASDAQ: XOMA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 17, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,647.75, up 0.07% and the NASDAQ Composite closed at 4,671.00, down 0.37%. The S&P 500 finished the session 0.07% higher at 2,041.32. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 781.08, up 0.49%, with the index advancing 9.06% in the previous three months. Register for your complimentary reports on these five stocks at:
DRNA: 21.30 (-0.06), GERN: 3.03 (unch), TKMR: 21.45 (-0.22), GALE: 1.68 (+0.06), XOMA: 3.41 (-0.01), EXEL: 2.48 (+0.20)
Tekmira inks deal with Dicerna
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 2:36PM CST
DRNA: 21.30 (-0.06), TKMR: 21.45 (-0.22)
Dicerna Reports on Progress of Development Programs
Business Wire - Mon Nov 17, 7:02AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ
RNA), a leader in the development of RNA interference (RNAi) based therapeutics, today announced that it will host its first R&D webcast to review the company's strategy, technology, and expanding pipeline of innovative RNAi therapies. The R&D webcast will take place on Monday, December 15 at 4:30 p.m. To register, please visit www.dicerna.com. DRNA: 21.30 (-0.06)
Dicerna Announces License Agreement with Tekmira to Advance Dicerna's PH1 Development Program
Business Wire - Mon Nov 17, 7:02AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ
RNA), a leading developer of RNA interference (RNAi) therapeutics, today announced a licensing agreement for Dicerna to use Tekmira's proprietary lipid nanoparticle (LNP) technology for delivery of DCR-PH1, Dicerna's investigational product candidate for primary hyperoxaluria type 1 (PH1), a rare, inherited liver disorder that often results in kidney failure, and for which there are no approved therapies. DRNA: 21.30 (-0.06)
Tekmira Announces Licensing and Collaboration Agreement With Dicerna
GlobeNewswire - Mon Nov 17, 7:00AM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM) a leading developer of RNA interference (RNAi) therapeutics, today announces a licensing and collaboration agreement with Dicerna Pharmaceuticals, Inc. Tekmira has licensed its proprietary lipid nanoparticle (LNP) delivery technology for exclusive use in Dicerna's primary hyperoxaluria type 1 (PH1) development program.
DRNA: 21.30 (-0.06), TKMR: 21.45 (-0.22), TKM.TO: 26.51 (-0.73)
Dicerna to Present at Two Upcoming Investor Conferences
Business Wire - Fri Nov 14, 3:40PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, today announced that Douglas M. Fambrough, Ph.D., President and CEO, will present at two upcoming conferences, including the Stifel 2014 Healthcare Conference and the Jefferies 2014 Global London Healthcare Conference.
DRNA: 21.30 (-0.06)
InsiderInsights.com Daily Round Up 11/10/14: CHK, TWX, SGEN, PBFX
InsiderInsights - at Seeking Alpha - Tue Nov 11, 2:29AM CST
HAS: 62.74 (+0.58), VR: 42.10 (+0.07), SEIC: 43.20 (+0.07), DRNA: 21.30 (-0.06), HA: 18.72 (-0.31), SAM: 303.26 (-0.97), PBFX: 23.40 (+0.95), AMRI: 16.94 (-0.28), GSAT: 2.40 (+0.08), TNET: 36.49 (+0.76), TWX: 83.87 (+0.56), HLT: 28.57 (+0.13), Q: 63.31 (+0.06), SGEN: 31.57 (+0.36), CF: 301.40 (-1.20), OPK: 13.80 (-0.28), CHK: 21.08 (+0.58), CNDO: 2.28 (+0.03), CO: 4.75 (-0.06), CPLA: 65.23 (-1.37)
Dicerna Pharmaceuticals' (DRNA) CEO Doug Fambrough on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 11:36AM CST
DRNA: 21.30 (-0.06)
Dicerna Pharmaceuticals beats by $0.09
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:24AM CST
DRNA: 21.30 (-0.06)
Dicerna Announces Third Quarter 2014 Financial and Operational Results
Business Wire - Thu Nov 06, 6:02AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, today announced financial and operational results for the quarter ended September 30, 2014.
DRNA: 21.30 (-0.06)
